This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Yet despite these and other claims , including those spreading on social media , there is as of yet no substantiated clinical data supporting either the prophylactic or therapeutic use of cannabis products in the treatment of COVID-19.
When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf.
The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. About Delic Corp, Inc.
A panel of Commonwealth Court judges has ordered the Wolf administration to reveal how many medical marijuana patients have received approval from a doctor to use cannabis for opioid addiction treatment. The newsroom specifically requested aggregate data — information that would not identify individual patients.
Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. (CSE:
In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. Even if there’s an accurate diagnosis, many mental health treatments have less-than-desirable efficacy, and there can be significant side effects.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
This hope comes from many individuals posting their stories (true or not) on social media. However, research has yet to provide us with a definitive answer as to whether or not RSO is effective as a cancer treatment. Let me explain to you the interesting tale behind it and give you a detail of what defines it. What Makes RSO Special?
The main goals with conducting clinical studies, which could include observational studies or clinical trials, are to explore the causes of a disease or its symptoms, test a treatment, and learn how a certain behaviour affects patients’ health. The trials focus on correlations between treatments and outcomes in real-world settings.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021. Net loss for the six months ended 30 June 2021 was $30.2 million, or $0.79 million) compared with $24.8 million, or $2.61
The Czech Republic legalized therapeutic cannabis for selected patients in 2015, and health insurance companies have been covering up to 90% of the cost of the treatment since 2020. According to official data cited by the Czech News Agency (CTK), the treatment helped improve the health condition and well-being of patients in 69% of cases.
The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized.
We believe that this will serve as a strong platform from which to deploy impactful alternative and psychedelic based treatment options,” stated Pouya Farmand, Chief Executive Officer of Levitee. Levitee Media Contact. media@leviteelabs.com. About Levitee Labs. The CSE (operated by CNSX Markets Inc.) ir@leviteelabs.com.
In adults with chronic pain , what are the harms of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the benefits of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the harms of cannabinoids? A Statement from the AHRQ.
The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.
16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Recent data suggest the US science knowledge is about the global average.
Johnson’s primary area of research expertise is the psychopharmacology of medications for treating addictions, and he is well known in the field for his discovery that topiramate, a gamma-aminobutyric acid (GABA) facilitator and glutamate antagonist, an effective treatment for alcoholism. ” About Ehave, Inc. Ehave, Inc.
This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA is aware of media reports of delta-8 THC products getting consumers “high.” brownies, gummies).
In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.
Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.
Similar statements were made through the course of the summer and fall, but in a November 16 statement to the media, Biden seemed to take a step backwards when he said: The truth of the matter is, there’s not nearly been enough evidence that has been acquired as to whether or not it is a gateway drug. Find Out if You Qualify.
In an official statement to media sources, Dr. Drake said ; “We don’t find any evidence to support the theory that cannabis functions as a gateway drug… if anything, we find that recreational cannabis legalization decreases opioid-related emergency department visits.”
To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.”. The FDA is collecting data to fill these gaps. The FDA has historically been passive in its oversight of CBD products.
The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. This is COMPASS’s 10 th patent overall, with five now granted in the US, two in the UK, one in Germany and two in Hong Kong.
After months of development, my partner and I built and successfully launched the beta for our cannabis data-analytics software, Jade Insights. It’s a software platform that helps cannabis businesses augment their process by providing insights for data-backed decision-making. ” JOHN KAGIA. ” OPHELIA CHONG.
It encourages patients to ask questions, provide accurate information, and participate in shared decision-making, leading to better treatment adherence and overall care quality. It replaces traditional paper-based forms and manual data entry, improving efficiency, accuracy, and patient experience. It also fosters active engagement.
We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.” Unlocking the genetic link will help point us towards treatment and a cure. Media Inquiries: Gabe Rodriguez. Forward-Looking Statement Disclaimer. Contact: Ehave Inc.
MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?
The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.
Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.
KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.
Researchers recruited 641 participants from Western Europe and America via Facebook groups, university mailing lists, and social media forums. The subjective nature of self-reported data can plague research. As a result, they possess more insight into climate change than individuals who don’t use psychedelics. Methamphetamine.
(“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, today announced the official, completed acquisition of Ketamine Wellness Centers Arizona LLC (“KWC”), becoming the largest chain of wellness centers providing ketamine treatments in the U.S.
The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.
All patients were carefully chosen from social media posts and Realm of Caring patient registries, with follow-up survey responses being collected from a subgroup of 190 participants. For example, rather than having researchers carry out a controlled investigation, each study subject provided self-reported data.
–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.
Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Media Enquiries: Sam Brown Inc.
The collection of data for the final study was through focused interviews with a snowball sample of eight participants who have experienced trying to enter the cannabis industry in Western City, California. Data were analyzed based on the central question, and three themes emerged. Central Research Question.
COVID-related border restrictions did not cause immediate major interruption to Australia’s drug markets, but wastewater data strongly indicates that the cumulative effect of these restrictions led to some substantial market interruptions. The latest report presents data on Australia’s drug consumption for 12 substances.
Clearly for the sake of our health and youth, we need more memes and less social media trolls. . About a year ago, data from the Strainprint app was used to analyze the impact of marijuana on depression, anxiety and stress. The data came from close to 12,000 entries (that’s a huge sample size!). So what does this all mean?
With its program in full swing, thousands of patients across the state are benefiting from access to this alternative form of treatment. From chronic pain to PTSD, patients with qualifying medical conditions have found solace in medical marijuana where traditional treatments may have fallen short.
The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “In
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content